Bind Research is a not-for-profit Focused Research Organisation dedicated to making disordered proteins—a class of biomolecules considered "undruggable" by mainstream pharma—viable drug targets. The organization is building a high-throughput platform to screen millions of small-molecule/disordered protein interactions, combining cellular and biophysical experiments with AI to ultimately predict drug candidates from protein sequences alone. It has also developed SpinForecast, an open-access NMR tool that accelerates backbone assignment for disordered proteins, reducing analysis time from weeks to under a minute.
Funding
Funding not disclosed
Founders
Product
Problem
Many incurable diseases involve biomolecules called disordered proteins, which continuously change their three-dimensional shapes and lack long-lived sites with which drug molecules can interact. These proteins are considered "undruggable" by the mainstream pharmaceutical industry, leaving a significant gap in therapeutic development for conditions involving these challenging targets.
Solution
Bind Research is a not-for-profit Focused Research Organisation (FRO) working to make disordered proteins druggable. The organization is building a high-throughput, parallel platform to probe millions of small-molecule/disordered protein interactions, combining cellular and biophysical experiments, computation, and AI to create an enormous dataset. This data will ultimately power an AI system that, given any disordered protein sequence, can predict promising drug candidates. Bind Research is committed to sharing its tools, AI software, and data publicly while protecting IP of specific potential drug molecules to ensure they can be developed into therapeutics. The organization also develops open-access tools like SpinForecast, which accelerates NMR backbone assignment for intrinsically disordered proteins, collapsing weeks of manual work into a computational task completed in under a minute.
Target Audience
Primary stakeholders include academic researchers studying disordered proteins, clinicians with unmet therapeutic needs, patient foundations focused on diseases involving IDPs, and pharmaceutical or biotech companies seeking collaborative partnerships in drug discovery.
Features
- High-throughput parallel screening platform probing millions of small-molecule/disordered protein interactions
- AI system under development to predict small-molecule binders from disordered protein sequences alone
- SpinForecast: open-access NMR backbone assignment tool using statistical patterns from the BMRB and AlphaFold2 predictions, achieving 100% confident assignments for ~40-75% of signals with >99% accuracy
- Chain-free assignment methodology that evaluates each signal independently, preventing ambiguous neighbors from derailing the full assignment
- Integration of cellular and biophysical experiments with computation and AI for comprehensive interaction mapping
- Public sharing of tools, AI software, and data while protecting IP of specific drug molecules for translational development